Date
- Thursday, 2 September 2010, All day
Location
- European Medicines Agency, Amsterdam, the Netherlands
On 2-3 September 2010, EMA hosted the first international scientific workshop on nanomedicines. Some 200 European and international participants from 27 countries including Australia, Canada, India, Japan and the United States discussed benefits and challenges arising from the application of nanotechnologies to medicines. Participants included representatives from patients' organisations, health care professionals' organisations, academia, regulatory authorities and pharmaceutical industry.
Documents
Summary report - Workshop on nanomedicines: 2-3 September 2010
English (EN) (3.74 MB - PDF)
Agenda - Workshop on nanomedicines: 2-3 September 2010
English (EN) (173.17 KB - PDF)
Presentation - Workshop on nanomedicines - Introduction, Patrick le Courtois, EMA
English (EN) (483.14 KB - PDF)
Presentation - Keynote lecture - Key ongoing applications in nanosciences and how they apply to pharmaceuticals, Rutledge Ellis-Behnke, MIT
English (EN) (38.7 MB - PDF)
Presentation - Engineering nanoparticles for biomedical applications, Mamoun Muhammed, Royal Institute of Technology, Stockholm
English (EN) (5.49 MB - PDF)
Presentation - Special aspects of nanomedicines: development, manufacturing and characterisation, Simon Holland, GlaxoSmithKline
English (EN) (1.11 MB - PDF)
Presentation - Special aspects of nanomedicines: Viewpoint from the industry, Jan Mà¶schwitzer, Abbott Healthcare Products B.V.
English (EN) (5.58 MB - PDF)
Presentation - Immunology and immunotoxicity of nanomedicines, Jacques Descotes, Lyon University Hospitals, France
English (EN) (193.45 KB - PDF)
Presentation - Nanotechnology - What about safety? How do we determine risk? Wim H de Jong, National Institute for Public Health and the Environment, Bilthoven
English (EN) (2.02 MB - PDF)
Presentation - Nanomedicines interaction with biological systems, Kenneth Dawson, University College of Dublin
English (EN) (5.14 MB - PDF)
Presentation - Nanomedicines on the market and in clinical development - Introduction, Eric Abadie, CHMP chair
English (EN) (751.58 KB - PDF)
Presentation - Liposomal nanomedicines and innovative formulations, Daan Crommelin, Utrecht University
English (EN) (1.64 MB - PDF)
Presentation - Polymer conjugates, Ruth Duncan, Cardiff University
English (EN) (11.72 MB - PDF)
Presentation - Nanoparticles, Rogà©rio Gaspar, University of Lisbon
English (EN) (4.31 MB - PDF)
Presentation - Novel and innovative nanotechnology-based delivery systems, Alexander Kabanov, University of Nebraska Medical Center
English (EN) (7.28 MB - PDF)
Presentation - Nanosystems in regenerative medicine, Jà¶ns Hilborn, Uppsala University
English (EN) (6.35 MB - PDF)
Presentation - Theranostics nanoparticles, Peter Dobson, Oxford University
English (EN) (2.69 MB - PDF)
Presentation - Safety specification - Identification and methodologies, Annalisa Rubino, EMA
English (EN) (465.75 KB - PDF)
Presentation - Pharmacovigilance and risk minimisation plans, Jan Petracek, PharmInvent
English (EN) (1.12 MB - PDF)
Presentation - Specific methodological issues and implications for risk assessment, Silvia Berkner, German Federal Environmental Agency
English (EN) (2.5 MB - PDF)
Presentation - Nanomedicines - Current initiatives in the US, Carlos Peà±a, FDA
English (EN) (164.16 KB - PDF)
Presentation - Nanomedicines - Current initiatives in Japan, Kumiko Sakai-Kato, Toru Kawanishi, National Institute of Health Sciences/MHLW
English (EN) (376.02 KB - PDF)
Presentation - Nanomedicines - Current initiatives in Canada, Duc Vu, Health Canada
English (EN) (372.3 KB - PDF)
Presentation - Way forward, Marisa Papaluca, EMA
English (EN) (392.09 KB - PDF)